India will be rolling out 400 doses of the new anti-TB medication delamanid in seven states in a pilot study using the drug.
Delamanid is the first in a new class of TB drugs called nitroimidazoles being developed to treat multi-drug resistant TB (MDR TB).
The drug will be provided to MDR TB patients from the states of Punjab, Rajasthan, Karnataka, Odisha, Kerala, Lakshadweep, according to reports.
All the patients will receive 100 mg delamanid tablets orally twice a day for 24 weeks in combination with a regimen of second-line TB drugs.
India received delamanid doses with the aid of the United States Agency for International Development (USAID).